Advertisement

Increased Risk Among Older Veterans of Prescribing Psychotropic Medication in the Absence of Psychiatric Diagnoses

Published:October 28, 2013DOI:https://doi.org/10.1016/j.jagp.2013.10.007

      Objective

      This study uses Veterans Health Administration (VHA) pharmacy and encounter claims to evaluate the use of psychotropic medications without a psychiatric diagnosis across age groups.

      Methods

      National VHA administrative data for fiscal year 2010 (FY2010) were used to identify all veterans who filled a prescription for at least one psychotropic medication from VHA (N = 1.85 million). Bivariate and multivariate analyses were used to compare the proportion of these veterans without any psychiatric diagnosis, across age groups, adjusting for possible medical indications. Analyses were repeated for six different classes of psychotropic medications and comparing mental health utilizers and non–mental health utilizers. Comparisons were made to prescribing of HIV and diabetes medications without an indicated diagnosis.

      Results

      Of all VHA patients prescribed a psychotropic medication in FY2010, 30% had no psychiatric diagnosis, with highest proportions among veterans ages 65–85. This practice was most frequent among nonmental health utilizers and far more prevalent for psychotropic medications than for HIV or diabetes medications. Logistic regression analysis found that age greater than 65 was the strongest predictor of being prescribed a psychotropic without a psychiatric diagnosis. Adjustment for possible medical use of psychotropics and overall medical comorbidity did not substantially alter these trends.

      Conclusion

      Older veterans, especially those not using specialty mental healthcare, are more likely to be prescribed psychotropic medications in the absence of a psychiatric diagnosis, perhaps representing unnecessary use, under-diagnosis of mental illness, or incomplete documentation.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Geriatric Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mojtabai R.
        • Olfson M.
        Proportion of antidepressants prescribed without a psychiatric diagnosis is growing.
        Health Aff (Millwood). 2011; 30: 1434-1442
        • Pagura J.
        • Katz L.Y.
        • Mojtabai R.
        • et al.
        Antidepressant use in the absence of common mental disorders in the general population.
        J Clin Psychiatry. 2011; 72: 494-501
        • Larson M.J.
        • Miller K.
        • Fleming K.J.
        Treatment with antidepressant medications in private health plans.
        Adm Policy Ment Health. 2007; 34: 116-126
        • Milea D.
        • Verpillat P.
        • Guelfucci F.
        • et al.
        Prescription patterns of antidepressants: findings from a US claims database.
        Curr Med Res Opin. 2010; 26: 1343-1353
        • Maust D.T.
        • Mavandadi S.
        • Eakin A.
        • et al.
        Telephone-based behavioral health assessment for older adults starting a new psychiatric medication.
        Am J Geriatr Psychiatry. 2011; 19: 851-858
        • Olfson M.
        • Blanco C.
        • Liu S.M.
        • et al.
        National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.
        Arch Gen Psychiatry. 2012; 69: 1247-1256
        • Wiechers I.R.
        • Leslie D.
        • Rosenheck R.
        Prescribing psychotropic medications in the absence of psychiatric diagnoses.
        Psychiatr Serv. 2013 Sep 3; (Epub ahead of print)
        • Pincus H.A.
        • Tanielian T.L.
        • Marcus S.C.
        • et al.
        Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.
        JAMA. 1998; 279: 526-531
      1. Medco Health Solutions. America's State of Mind: A Report by Medco, 2011. Available at: http://apps.who.int/medicinedocs/documents/s19032en/s19032en.pdf. Accessed October 29, 2013

        • Mojtabai R.
        Increase in antidepressant medication in the US adult population between 1990 and 2003.
        Psychother Psychosom. 2008; 77: 83-92
        • Mark T.L.
        • Levit K.R.
        • Buck J.A.
        Datapoints: psychotropic drug prescriptions by medical specialty.
        Psychiatr Serv. 2009; 60: 1167
        • Mojtabai R.
        • Olfson M.
        National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication.
        J Clin Psychiatry. 2008; 69: 1064-1074
        • Klap R.
        • Unroe K.T.
        • Unutzer J.
        Caring for mental illness in the United States: a focus on older adults.
        Am J Geriatr Psychiatry. 2003; 11: 517-524
        • Zubenko G.S.
        • Sunderland T.
        Geriatric psychopharmacology: why does age matter?.
        Harv Rev Psychiatry. 2000; 7: 311-333
        • Jenike M.A.
        Psychiatric illnesses in the elderly: a review.
        J Geriatr Psychiatry Neurol. 1996; 9: 57-82
      2. Mulsant BH, Pollock BG: Psychopharmacology, in The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th edition. Edited by Blazer DG, Steffens DC. Arlington, VA, American Psychiatric Publishing, 2009; 453–483

        • Ray W.A.
        • Griffin M.R.
        • Schaffner W.
        • et al.
        Psychotropic drug use and the risk of hip fracture.
        N Engl J Med. 1987; 316: 363-369
        • Glass J.
        • Lanctot K.L.
        • Herrmann N.
        • et al.
        Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.
        BMJ. 2005; 331: 1169
        • Kales H.C.
        • Valenstein M.
        • Kim H.M.
        • et al.
        Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.
        Am J Psychiatry. 2007; 164 (quiz 1623): 1568-1576
        • Schneider L.S.
        • Dagerman K.S.
        • Insel P.
        Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
        JAMA. 2005; 294: 1934-1943
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Institute of Medicine
        The Mental Health and Substance Abuse Workforce for Older Adults.
        in: Whose Hands? National Academies Press, Washington, DC2012
        • Rost K.
        • Smith R.
        • Matthews D.B.
        • et al.
        The deliberate misdiagnosis of major depression in primary care.
        Arch Fam Med. 1994; 3: 333-337
        • Freeman V.G.
        • Rathore S.S.
        • Weinfurt K.P.
        • et al.
        Lying for patients: physician deception of third-party payers.
        Arch Intern Med. 1999; 159: 2263-2270
        • Fournier J.C.
        • DeRubeis R.J.
        • Hollon S.D.
        • et al.
        Antidepressant drug effects and depression severity: a patient-level meta-analysis.
        JAMA. 2010; 303: 47-53
        • Gibbons R.D.
        • Hur K.
        • Brown C.H.
        • et al.
        Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
        Arch Gen Psychiatry. 2012; 69: 572-579
        • Kirsch I.
        • Deacon B.J.
        • Huedo-Medina T.B.
        • et al.
        Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.
        PLoS Med. 2008; 5: e45